Cross-Over Evaluation of Two Lubricating Eye Drops

This study has been completed.
Information provided by:
Innovative Medical Identifier:
First received: June 26, 2007
Last updated: January 11, 2008
Last verified: January 2008
To evaluate the efficacy of two lubricating eye drops for the treatment of dry eye signs and symptoms.

Condition Intervention Phase
Dry Eye
Drug: Polyethylene Glycol 400 0.4%
Drug: Propylene Glycol 0.3%
Drug: 0.15% sodium Hyaluronate
Drug: sodium chloride
Drug: sodium phosphate monobasic
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single Blind

Resource links provided by NLM:

Further study details as provided by Innovative Medical:


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both

Inclusion Criteria:

  1. Patients 18 yrs or older
  2. Males or females
  3. Any race or ethnic background
  4. Patients with present ocular surface discomfort and a SESoD score of at least 2

Exclusion Criteria:

  1. Corneal refractive surgery within 6 months of this study.
  2. Contact lens use on day of examination.
  3. Corneal ectasia.
  4. Current use of Restasis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00493662

United States, Pennsylvania
Hazleton Eye Specialists
Hazleton, Pennsylvania, United States, 18202
Sponsors and Collaborators
Innovative Medical
Principal Investigator: Tom Kislan, OD Hazleton Eye Specialists
  More Information Identifier: NCT00493662     History of Changes
Other Study ID Numbers: 5310 
Study First Received: June 26, 2007
Last Updated: January 11, 2008
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Viscosupplements processed this record on May 05, 2016